Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression

This publication has 25 references indexed in Scilit:

• Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
  Journal of Clinical Oncology, 2007
• A tumor suppressor and oncogene: the WT1 story
  Leukemia, 2007
• Normal and leukaemic stem cells
  British Journal of Haematology, 2005
• Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
  Leukemia, 2005
• Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy
  Leukemia, 2005
• Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
  Blood, 2004
• WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study
  British Journal of Haematology, 2004
• A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia
  The Hematology Journal, 2004
• Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
  Journal of Clinical Oncology, 2003
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
  Nature Medicine, 1997